WXXWY News and Press, Wuxi Biologics Cayman Inc ADR From 02/18/20

SHANGHAI , Feb. 18, 2020 /PRNewswire/ -- WuXi Vaccines, a new vaccine Contract Development and Manufacturing Organization (CDMO) established between WuXi Biologics (stock code: 2269.HK) and Shanghai Hile Bio-technology (stock code: 603718.SH) announced that it has entered into a strategic...

SHANGHAI , Feb. 12, 2020 /PRNewswire/ -- WuXi Biologics is closely monitoring the coronavirus outbreak. Our management team is working vigilantly to execute our Business Continuity Plan to mitigate any potential risk. All three operating sites in China , namely Wuxi, Shanghai and ...

SHANGHAI , Jan. 29, 2020 /PRNewswire/ -- The coronavirus outbreak is having a potentially significant social and economic impact in China . WuXi Biologics is closely monitoring the coronavirus outbreak and is complying with guidance from the relevant authorities. Our management team is w...

SHANGHAI , Jan. 29, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, has stepped up its efforts in enabling the development o...

WuXi Biologics ( OTCPK:WXXWY ) will take over the operations of one of Bayer's ( OTCPK:BAYRY ) final drug product manufacturing plants in Leverkusen, Germany, and purchase the associated equipment, in combination with a long-term lease contract for the building. More news ...

First drug product facility in Europe to complement WuXi Biologics' existing commercial manufacturing capacities WuXi Biologics will be the back-up manufacturer for Kovaltry™ of Bayer SHANGHAI and LEVERKUSEN, Germany, Jan. 16, 2020 /PRNewswire/ -- WuXi Biologi...

Almirall S.A. ( OTC:LBTSF ) is starting the new year with a flurry of deals. More news on: Almirall, S.A., Wuxi Biologics (Cayman) Inc ADR, WuXi Biologics (Cayman) Inc., Healthcare stocks news, Read more ...

BARCELONA, Spain , Jan. 9, 2020 /PRNewswire/ -- Almirall, S.A. (ALM)  and WuXi Biologics ("WuXi Bio") (2269.HK) have today announced the signing of an agreement. Through this collaboration Almirall embarks on its strategy to develop highly innovative biologic products for dermatol...

The 12 th global licensing partnership for WuXiBody™ since its launch in August 2018 showcasing the power and versatile applications of WuXiBody™ in multiple therapeutic areas SHANGHAI and BARCELONA, Spain , Jan. 9, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (...

SHANGHAI , Jan. 2, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its partner OncoImmune on the U.S. Foo...